3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
18
Other hematologic neoplasm
3
Dermatologic
3
Thoracic
2
Plasma cell
2
Head & Neck
2
Gynecologic
2
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Multiple Myeloma
27
Hodgkin Disease
3
Breast Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Waldenstrom Macroglobulinemia
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Cyclophosphamide
71
fludarabine phosphate
67
Peripheral Blood Stem Cell Transplantation
60
Mycophenolic Acid
52
Whole-Body Irradiation
42
Cyclosporine
39
Tacrolimus
38
Busulfan
35
Antilymphocyte Serum
35
Filgrastim
29
Radiotherapy
27
Methotrexate
24
Melphalan
20
Cord Blood Stem Cell Transplantation
19
Methylprednisolone
17
Etoposide
15
fludarabine
11
Therapeutics
10
Flow Cytometry
10
Sirolimus
9
Psychiatric Rehabilitation
8
Granulocyte Colony-Stimulating Factor
8
Cytarabine
8
sargramostim
7
Rituximab
7
Polymerase Chain Reaction
7
Bortezomib
7
Transplantation
6
Alemtuzumab
6
Thiotepa
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
pembrolizumab
×
Plasma cell
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts
NCT01953692
2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1
Completed
197 enrolled
52 charts